tiprankstipranks
Trending News
More News >
Arbutus Biopharma (ABUS)
:ABUS
Advertisement

Arbutus Biopharma (ABUS) Price & Analysis

Compare
1,260 Followers

ABUS Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Financial ManagementArbutus ended 2024 with $123M in cash and highlighted a 'continued focus on efficient deployment of financial resources and personnel.'
Legal ProceedingsA positive outcome to the Markman hearing was viewed as favorable for Arbutus.
Product DevelopmentAnalyst recommends a Buy rating, affirming confidence in the potential of imdusiran as a core component for achieving a functional cure in HBV.
Bears Say
Clinical TrialsArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.
Legal ChallengesArbutus and partner Genevant expand their LNP legal activity against Moderna globally.
Restructuring CostsArbutus anticipates a one-time restructuring charge of ~$11M-$13M in 1Q25.

Arbutus Biopharma News

ABUS FAQ

What was Arbutus Biopharma’s price range in the past 12 months?
Arbutus Biopharma lowest stock price was $2.71 and its highest was $5.10 in the past 12 months.
    What is Arbutus Biopharma’s market cap?
    Arbutus Biopharma’s market cap is $845.39M.
      When is Arbutus Biopharma’s upcoming earnings report date?
      Arbutus Biopharma’s upcoming earnings report date is Nov 05, 2025 which is in 38 days.
        How were Arbutus Biopharma’s earnings last quarter?
        Arbutus Biopharma released its earnings results on Aug 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.048 by $0.058.
          Is Arbutus Biopharma overvalued?
          According to Wall Street analysts Arbutus Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Arbutus Biopharma pay dividends?
            Arbutus Biopharma does not currently pay dividends.
            What is Arbutus Biopharma’s EPS estimate?
            Arbutus Biopharma’s EPS estimate is -0.03.
              How many shares outstanding does Arbutus Biopharma have?
              Arbutus Biopharma has 191,698,700 shares outstanding.
                What happened to Arbutus Biopharma’s price movement after its last earnings report?
                Arbutus Biopharma reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.048. Following the earnings report the stock price went up 1.76%.
                  Which hedge fund is a major shareholder of Arbutus Biopharma?
                  Currently, no hedge funds are holding shares in ABUS

                  Company Description

                  Arbutus Biopharma

                  Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with hepatitis B virus (HBV) infections and other viral diseases. The company specializes in discovering and commercializing novel drug candidates that target the underlying biology of HBV to improve patient outcomes. Arbutus's core products include a range of antiviral therapies, particularly those that aim to eliminate HBV or significantly reduce viral load in patients.

                  Arbutus Biopharma (ABUS) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Geron
                  Immatics
                  Immunome
                  Praxis Precision Medicines
                  Sana Biotechnology

                  Ownership Overview

                  1.15%10.56%24.02%54.88%
                  24.02% Other Institutional Investors
                  54.88% Public Companies and
                  Individual Investors
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis